$2.13
-0.09[-4.05%]
At close: Apr 19
$2.18
0.0500[2.35%]
After Hours: 7:42AM EDT
Regulus Therapeutics
(NASDAQ:RGLS)Regulus Therapeutics Stock (NASDAQ:RGLS), Analyst Ratings, Price Targets, Predictions
Regulus Therapeutics Inc has a consensus price target of $5.5, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Canaccord Genuity, and Leerink Partners on March 25, 2024, March 19, 2024, and March 18, 2024. With an average price target of $8.67 between HC Wainwright & Co., Canaccord Genuity, and Leerink Partners, there's an implied 297.55% upside for Regulus Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Leerink Partners
Wells Fargo
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Regulus Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/25/2024 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 404.59% | Canaccord Genuity | Whitney Ijem | $12 → $11 | Maintains | Buy | Get Alert |
| 03/18/2024 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 175.23% | Leerink Partners | Joseph Schwartz | → $6 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 37.61% | Wells Fargo | Jim Birchenough | $2 → $3 | Maintains | Equal-Weight | Get Alert |
| 09/21/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 450.46% | Canaccord Genuity | Whitney Ijem | $9 → $12 | Maintains | Buy | Get Alert |
| 09/21/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/21/2023 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | HC Wainwright & Co. | Raghuram Selvaraju | $20 → $9 | Maintains | Buy | Get Alert |
| 11/08/2022 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | 312.84% | Canaccord Genuity | Whitney Ijem | → $9 | Initiates | → Buy | Get Alert |
| 09/02/2021 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | -8.26% | Cantor Fitzgerald | Brian Cheng | — | Initiates | → Overweight | Get Alert |
| 05/14/2021 | RGLS | Buy Now | Regulus Therapeutics | $2.18 | -8.26% | HC Wainwright & Co. | — | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Regulus Therapeutics (RGLS)?
The latest price target for Regulus Therapeutics (NASDAQ: RGLS) was reported by HC Wainwright & Co. on March 25, 2024. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 322.54% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Regulus Therapeutics (RGLS)?
The latest analyst rating for Regulus Therapeutics (NASDAQ: RGLS) was provided by HC Wainwright & Co., and Regulus Therapeutics reiterated their buy rating.
When was the last upgrade for Regulus Therapeutics (RGLS)?
There is no last upgrade for Regulus Therapeutics.
When was the last downgrade for Regulus Therapeutics (RGLS)?
There is no last downgrade for Regulus Therapeutics.
When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.
Is the Analyst Rating Regulus Therapeutics (RGLS) correct?
While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $2.13, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.